Ivantis Revenue and Competitors



Total Funding

Estimated Revenue & Valuation

  • Ivantis's estimated annual revenue is currently $19.3M per year.(i)
  • Ivantis received $25.0M in venture funding in January 2017.
  • Ivantis's estimated revenue per employee is $251,000
  • Ivantis's total funding is $132.4M.

Employee Data

  • Ivantis has 77 Employees.(i)
  • Ivantis grew their employee count by -8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Ivantis News

2022-04-19 - Micro Invasive Glaucoma Surgery (MIGS) Devices Market Size ...

Key Players – Glaukos Corporation, Ivantis, Allergan, Ellex – The New York Irish Emgirant...

2022-03-22 - Novel MIGS and Meds That Improve Glaucoma Management

... Equinox, Ivantis, Sight Sciences, TearClear, ViaLase ... Elios Vision, Ellex, Glaukos, iSTAR, Ivantis, New World Medical, Nicox,...

2021-09-15 - Ivantis Announces Settlement of Glaukos Patent Litigation

IRVINE, Calif., Sept. 15, 2021 /PRNewswire/ -- Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corpo ...

2020-11-17 - Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

IRVINE, Calif., Nov. 17, 2020 /PRNewswire/ -- Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, announced today that the American Academy of Ophthalmology (AAO) has desig ...

2019-08-31 - Study Shows MIGS Makes up Nearly Half of Glaucoma ...

There are four FDA-approved MIGS stents: the Glaukos's iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. That number could ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Ivantis Funding

DateAmountRoundLead InvestorsReference
2013-02-04$27.0MBAscension Health VenturesArticle
2013-08-21$5.0MBEDBI of SingaporeArticle
2014-09-24$25.0MBForesite CapitalArticle
2017-01-10$25.0MCRA Capital ManagementArticle